pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,164 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1788Endpoints1392Fierce Biotech712BioSpace702BioPharma Dive526raps234onclive165fda recalls113
therapy area
allOncology12362Rare Disease3231Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • UC Berkeley spinout explores gene-editing approach to GLP-1 based weight-loss therapy
    UC Berkeley researchers have launched a startup that plans to use jumping genes to deliver GLP-1 gene therapy for obesity treatment. The approach seeks to create a long-lasting source of the hormon…
    Endpoints · 6mo agoNeutral↗ source
  • Guest-edited journal issues face mass retractions over compromised peer review
    A recent retraction by the British Medical Journal’s publishing group removed almost an entire special issue of the Journal of Medical Genetics that focused on cancer immunotherapies. The journal…
    STAT · 6mo agoNegative↗ source
← prev
page 166 of 167
next →
fda medwatch111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1064
Pain778
Endocrinology & Metabolism777
Nephrology762
International childhood vaccine campaign expands, newsletter reports
The latest Morning Rounds newsletter notes that a global campaign to increase childhood vaccination rates is gaining momentum. The piece highlights the growing reach of the effort without providing…
STAT · 6mo agoNeutral↗ source
  • Daiichi Sankyo delays release of annual results, shares fall
    Daiichi Sankyo announced it will postpone the reporting of its annual results, saying more time is needed to finalize the numbers. The company had planned to unveil the financials for its fiscal y…
    Endpoints · 6mo agoNegative↗ source
  • Pfizer strategy chief Andrew Baum departs, stays on as senior advisor; Helus Pharma appoints new CEO after two months
    Andrew Baum, formerly chief strategy and innovation officer at Pfizer, has left that role. He will continue to work with the company as a senior strategic advisor to CEO Albert Bourla. Meanwhile,…
    Endpoints · 6mo agoNeutral↗ source
  • Tenpoint Therapeutics appoints Stephen Lane as chief medical officer
    STAT+ columnist Ed Silverman highlights recent personnel moves in the pharma sector. This week’s note focuses on a new senior appointment at Tenpoint Therapeutics. The company has hired Stephen La…
    STAT · 6mo agoNeutral↗ source
  • Local news shutdown threatens health reporting, but Pittsburgh Post-Gazette finds a lifeline
    The decline of local news outlets is eroding the coverage of health and science topics that communities rely on for accurate information. In early January, the Pittsburgh Post-Gazette, Western Pen…
    STAT · 6mo agoNegative↗ source
  • Veteran neonatal nurse practitioner begins medical school at 69 and prepares for family-medicine residency at 72
    Dawn Zuidgeest-Craft, a 69-year-old, is about to begin medical school after a career spanning more than four decades as a neonatal nurse practitioner. She aims to complete her training and start a…
    STAT · 6mo agoPositive↗ source
  • Regeneron secures first FDA approval for gene therapy treating rare inherited hearing loss
    Regeneron announced that the U.S. Food and Drug Administration has approved its gene-based treatment Otarmeni, marking the first approval of a therapy for inherited hearing loss. The therapy is de…
    Endpoints · 6mo agoApprovalPositive↗ source
  • FDA approves Regeneron’s Otarmeni gene therapy for rare inherited hearing loss
    The FDA has approved Otarmeni, a gene therapy from Regeneron, marking the first therapy cleared under the agency’s national priority voucher program and will be provided to eligible patients at no…
    BioPharma Dive · 6mo agoApprovalPositive↗ source
  • AbbVie to invest $1.4 billion in new 185-acre manufacturing campus in Durham, North Carolina
    AbbVie announced a $1.4 billion investment to build a large manufacturing campus in Durham, North Carolina. The 185-acre site will focus on producing small-volume parenteral medicines such as vial…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • Sanofi beats Q1 sales forecasts, driven by strong Dupixent demand
    Sanofi reported first‑quarter results that exceeded Wall Street expectations, with net sales rising 6.2% to €10.5 billion (about $12.3 billion).\n\nThe growth was led by Dupixent, the anti‑inflamma…
    BioPharma Dive · 6mo agoEarningsPositive↗ source
  • Novo Nordisk's GLP-1 pill shows blood-sugar reduction in teens with type 2 diabetes
    Novo Nordisk reported results from a study evaluating its oral GLP-1 therapy, Rybelsus, in adolescents with type 2 diabetes. The trial enrolled participants aged 10-17 who took the pill for roughl…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Roche remains bullish on giredestrant despite first-line trial setback
    Roche's CEO Thomas Schinecker said the company still expects its investigational oral breast cancer therapy giredestrant to generate strong sales, potentially surpassing Herceptin. The optimism fo…
    Endpoints · 6mo agoNegative readoutNeutral↗ source
  • Trump touts completion of first round of White House drug pricing deals with Regeneron
    President Trump announced that a pricing agreement with Regeneron marks the final deal of an initial slate of 17 sought by the administration. Under the private arrangement, Regeneron will lower Me…
    STAT · 6mo agoDealNeutral↗ source
  • Trump administration allocates $50 million to psychedelic research and moves to downgrade medical marijuana
    President Trump signed an executive order that earmarks $50 million for research into psychedelics as potential mental‑health treatments and directs the FDA to accelerate their review process. The…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Novartis' Lutathera radioligand therapy may soon face first generic challenger
    Novartis has built a sizable business delivering radioligand therapies, with Lutathera being a leading product. A rival company is preparing to launch the first generic version, which could introd…
    Endpoints · 6mo agoNegative↗ source
  • Sanofi’s research focus may shift under new CEO Belén Garijo, amid gene therapy advances and telehealth debates
    Sanofi is entering a period of strategic reassessment as Belén Garijo assumes the chief executive role. Observers are watching to see whether the company will adjust its recent emphasis on immunolo…
    STAT · 6mo agoNeutral↗ source
  • Roche eyes up to $9 billion annual sales from breast cancer pill and obesity drug pipeline amid biosimilar pressure
    Roche reported first‑quarter earnings that showed a 5% dip in reported revenue, driven by a weaker U.S. dollar against the Swiss franc. On a constant‑currency basis, sales rose 6% to 14.7 billion S…
    BioPharma Dive · 6mo agoEarningsNeutral↗ source
  • Amneal to acquire biosimilar maker for $375 million upfront
    Amneal Pharmaceuticals announced it will purchase a biosimilar development company, agreeing to pay $375 million in an upfront cash payment. The deal expands Amneal’s portfolio in the growing biosi…
    Endpoints · 6mo agoDealNeutral↗ source
  • CAR-T biotech Kelonia rebounds from cash crises to a $3 billion sale, while drugmakers explore Prescribery partnership
    The latest episode of STAT's "The Readout LOUD" podcast focuses on a dramatic turnaround at a CAR‑T biotech that faced near‑bankruptcy three times before being bought for more than $3 billion. The…
    STAT · 6mo agoPositive↗ source
  • Sanofi defends Garijo appointment and reaffirms commitment to immunology ahead of new CEO
    Sanofi held its first-quarter earnings call, with CFO François-Xavier Roger fielding questions from the media. During the call he defended the recent appointment of Belén Garijo, formerly of Merck…
    Endpoints · 6mo agoEarningsNeutral↗ source
  • Substance-use disorder biotech Tempero Bio shuts down after serious safety incident
    Tempero Bio, a biotech focused on treatments for substance use disorders, announced it will cease operations. The decision follows a serious adverse event that occurred during the company's develo…
    Endpoints · 6mo agoNegative↗ source
  • Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk
    Since the 1918 pandemic, the military has acknowledged the threat of influenza. Now that’s changing.
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Endpoints News earns three Neal Awards for Trump coverage, CRISPR series and JPM event
    Endpoints News was honored with three Neal Awards in 2026. The awards recognize its reporting on the pharmaceutical industry's interactions with the Trump administration, a three-part series explo…
    Endpoints · 6mo agoPositive↗ source